HLN - Haleon plc

NYSE - Nasdaq Real Time Price. Currency in USD
+0.06 (+0.73%)
At close: 04:00PM EDT
8.31 +0.05 (+0.67%)
After hours: 07:14PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
Previous Close8.20
Bid8.15 x 4000
Ask8.42 x 3200
Day's Range8.22 - 8.32
52 Week Range5.59 - 9.05
Avg. Volume4,958,290
Market Cap38.139B
Beta (5Y Monthly)N/A
PE Ratio (TTM)27.53
Earnings DateN/A
Forward Dividend & Yield0.06 (0.70%)
Ex-Dividend DateMar 16, 2023
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-16% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for HLN

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Zacks

    HLN or SYK: Which Is the Better Value Stock Right Now?

    HLN vs. SYK: Which Stock Is the Better Value Option?

  • Benzinga

    GSK Trims Stake On Consumer Business Spin Off, Raises £804M

    GSK Plc (NYSE: GSK) sold 240 million shares of its spun-out consumer healthcare group Haleon Plc (NYSE: HLN) in a move that has raised £804 million for the firm. The offloaded shares are equivalent to up to 2.5% of Haleon's issued share capital. Following the settlement of the placing, GSK will hold 955 million ordinary shares in Haleon, representing approximately 10.3% of its issued share capital. GSK and Pfizer Inc (NYSE: PFE) – which hold a 32% stake in Haleon – have each undertaken not to di

  • Yahoo Finance UK

    Trending tickers: GSK | THG | Beazley | Disney

    The latest investor updates on stocks that are trending on Friday.

  • Benzinga

    Pharma Giant Pfizer To Start Selling Haleon Stake Within Months, CFO Says

    Pfizer Inc (NYSE: PFE) is reportedly looking to start selling its stake in Haleon plc (NYSE: HLN). In June last, the pharma giant announced its plans to exit the ownership interest in Haleon in a disciplined manner after the demerger. Pfizer's CFO, Dave Denton, told the Financial Times that it intends to offload that stake in a "slow and methodical" manner within months. Pfizer retained its 32% stake in Haleon. GSK Plc (NYSE: GSK) has up to 13.5% in Haleon, while GSK shareholders will own the re

  • Reuters

    UPDATE 2-Haleon quarterly profit squeezed by higher costs

    Haleon, the world's biggest standalone consumer health business, on Wednesday reported first-quarter profit below analyst expectations, hurt by higher costs. The company, which sells non-prescription drugs, vitamins and oral care products, said it generated earnings per share of 4.2 pence on revenue of nearly 3 billion pounds. Organic revenue growth of 9.9% in the quarter was largely driven by price increases, but also a small rise in volumes.

  • Barrons.com

    Why J&J’s Kenvue Spinoff Is Just What the IPO Doctor Ordered

    The consumer health company features a range of leading brands, a relatively cheap valuation, a solid balance sheet, consistent earnings, and a healthy dividend yield. It’s no tech unicorn, a good thing in 2023.

  • Barrons.com

    J&J’s $40 Billion Spinoff Could Rule Consumer Health. But It Has One Rival.

    On Monday afternoon, Johnson & Johnson which owns each of these brands, put a number on it: About $40 billion. Johnson & Johnson is pricing the IPO at between $20 and $23 per share, and expects to raise about $3.2 billion. At a valuation of $40 billion, Kenvue represents about 9% of Johnson & Johnson’s current market value f $426 billion.

  • Simply Wall St.

    Calculating The Intrinsic Value Of Haleon plc (LON:HLN)

    Key Insights The projected fair value for Haleon is UK£3.15 based on 2 Stage Free Cash Flow to Equity Haleon's UK£3.45...

  • Insider Monkey

    Aristotle Global Equity Strategy Sold Haleon plc (HLN) for More Compelling Opportunities

    Aristotle Capital Management, LLC, an investment management company, released its “Global Equity Strategy” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, the fund returned 12.67% net of fees, compared to a 9.77% return for the MSCI World Index (net) and a 9.76% return for the MSCI ACWI […]

  • Simply Wall St.

    Insiders who bought Haleon plc (LON:HLN) last year must be regretting not buying more as market cap hits UK£30b

    Haleon plc ( LON:HLN ) insiders who purchased shares in the last 12 months were richly rewarded last week. The stock...

  • Barrons.com

    GSK, Haleon Shares Drop After Setback on Zantac Cancer Litigation

    Nearly four months after a federal court ruling eased investors' concerns, a decision by a state judge in California has reignited those fears.

  • Simply Wall St.

    Haleon plc Just Missed Earnings - But Analysts Have Updated Their Models

    Shareholders might have noticed that Haleon plc ( LON:HLN ) filed its annual result this time last week. The early...

  • Reuters

    GSK spinoff Haleon has no deals on immediate horizon

    Consumer healthcare group Haleon's Chief Executive Brian McNamara said on Thursday he does not expect to announce any acquisitions or divestments imminently, amid analyst concerns its 2023 cost forecasts could hit consensus profit estimates. McNamara told Reuters that both types of transactions were on the cards, but added "there's certainly nothing imminent that is out there that I would talk about today". Haleon, carved out of British drugmaker GSK in July in the biggest listing in Europe for more than a decade, is the world's biggest standalone consumer health business selling non-prescription drugs, vitamins and oral care products.

  • Reuters

    UPDATE 3-GSK spinoff Haleon forecasts 4-6% revenue growth in 2023

    Haleon, the world's biggest standalone consumer health business with brands such as Sensodyne toothpaste and Advil painkillers, on Thursday forecast 4-6% organic revenue growth in 2023. In its first full-year results, CEO Brian McNamara said Haleon had navigated a highly volatile environment. Players in the consumer health field, like other sectors, have had to contend with sharp cost increases across the business, including raw materials, transport and energy linked to the war in Ukraine and lingering COVID-19 disruptions.

  • Simply Wall St.

    Haleon plc's (LON:HLN) largest shareholders are public companies with 45% ownership, institutions own 42%

    A look at the shareholders of Haleon plc ( LON:HLN ) can tell us which group is most powerful. The group holding the...

  • Insider Monkey

    10 Recent Spin-off Companies That Hedge Funds Are Piling Into

    In this article, we discuss 10 recent spin-off companies that hedge funds are piling into. If you want to see more stocks in this selection, check out 5 Recent Spin-off Companies That Hedge Funds Are Piling Into. A spin-off occurs when a company splits off a portion of its business into a separate company and […]

  • Insider Monkey

    Is This the Time to Add Haleon plc (HLN) to Your Portfolio?

    Cooper Investors, an investment management firm, released its “Cooper Investors Global Equities Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. The fund returned 6.24% in the fourth quarter, compared to a 7.08% return for the benchmark MSCI ACWI. For the year 2022, the fund returned -24.69% compared to a […]

  • Zacks

    GSK's New Drugs and Pipeline Hold the Key to Growth in 2023

    GSK's specialty products like Dovato, Nucala, Trelegy Ellipta and Shingrix are likely to drive sales, making up for the lower sales of established drugs due to generic erosion.

  • Insider Monkey

    12 Best 52-Week High Stocks To Buy Now

    In this article, we will take a look at the 12 best 52-week high stocks to buy now. If you want to see more stocks in this selection, go to the 5 Best 52-Week High Stocks To Buy Now. The equity markets have been taking a beating this year as the Dow Jones Industrial Average […]

  • Simply Wall St.

    Haleon plc (LON:HLN) Delivered A Weaker ROE Than Its Industry

    Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...

  • Insider Monkey

    10 Best Medical Stocks Under $20

    In this article, we discuss 10 best medical stocks under $20. If you want to see more stocks in this selection, check out 5 Best Medical Stocks Under $20. The healthcare industry has undergone a significant restructuring in the wake of the COVID-19 pandemic. There were multiple new healthcare trends in 2022 that have a […]

  • The Telegraph

    This once good company has created two great ones – investors should own both

    Market noise has been loud this year and it has been difficult for investors to look beyond the hysteria whipped up by their peers to focus on information and fundamentals. Sentiment has also been highly changeable, which has led to volatile stock prices that in many cases materially diverge from underlying business valuations.

  • Insider Monkey

    Should You Add Haleon plc (HLN) to Your Portfolio?

    Ariel Investments, an investment management company, released its “Ariel Global Fund” third-quarter investor letter. A copy of the same can be downloaded here. In the third quarter, the fund declined -10.05%, underperforming the MSCI ACWI Index and the MSCI ACWI Value Index, which returned -6.82% and -7.66%, respectively. Multiple headwinds from all over the world affected […]

  • Insider Monkey

    Is Haleon plc (HLN) a Good Investment Avenue?

    Aristotle Capital Management, LLC, an investment management company, released its “International Equity Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, the fund returned ‐7.90% gross of fees, compared to a ‐9.36% return for the MSCI EAFE Index and ‐9.91% return for the MSCI ACWI ex USA […]

  • Simply Wall St.

    Haleon Reports Third Quarter 2022 Earnings

    Haleon ( LON:HLN ) Third Quarter 2022 Results Key Financial Results Net income: UK£345.0m (up by UK£345.0m from 3Q...